The Leading Community for Trusted Peptide Research & Insights
Join a vibrant community sharing real peptide experiences, clinical research, and proven protocols. Data-backed, open, and censorship-free.
CJC-1295 is a synthetic GHRH (Growth Hormone-Releasing Hormone) analog with extended duration due to Drug Affinity Complex technology. Studied for its effects on growth hormone release and body composition.
Summary: Stimulates growth hormone release by activating GHRH receptors on pituitary cells, leading to elevated IGF-1 and anabolic effects. Mechanisms (reported/proposed across domains): Growth hormone axis • Binds to GHRH receptors on pituitary somatotroph cells, triggering signaling cascades that promote GH synthesis and release. • Stimulates pulsatile GH secretion, leading to 2-10x elevation...
Investigational - Trials Discontinued
Dose: 100–300 mcg (no DAC) · Route: Subcutaneous (SC) · Frequency: 1–3× daily · Duration: 8–12 weeks
Join a vibrant community sharing real peptide experiences, clinical research, and proven protocols. Data-backed, open, and censorship-free.